Differences in the mode of action of cyclosporine and FK 506.
Hutchinson
I V
IV
School of Biological Sciences, University of Manchester, UK.
Bagnall
W
W
Bryce
P
P
Pufong
B
B
Geraghty
P
P
Brogan
I
I
D000818:Animals; D002352:Carrier Proteins / Q000378:metabolism; D016572:Cyclosporine / Q000494:pharmacology*; D016207:Cytokines / Q000096:biosynthesis / Q000502:physiology; D004268:DNA-Binding Proteins / Q000378:metabolism; D006360:Heat-Shock Proteins / Q000378:metabolism; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D050778:NFATC Transcription Factors; D009687:Nuclear Proteins; D018121:Receptors, Cytokine / Q000096:biosynthesis / Q000502:physiology; D011965:Receptors, Glucocorticoid / Q000096:biosynthesis / Q000187:drug effects / Q000502:physiology; D011994:Recombinant Proteins / Q000096:biosynthesis; D016559:Tacrolimus / Q000494:pharmacology*; D022021:Tacrolimus Binding Proteins; D014157:Transcription Factors / Q000378:metabolism; D014162:Transfection
D002352:Carrier Proteins; D016207:Cytokines; D004268:DNA-Binding Proteins; D006360:Heat-Shock Proteins; D007166:Immunosuppressive Agents; D050778:NFATC Transcription Factors; D009687:Nuclear Proteins; D018121:Receptors, Cytokine; D011965:Receptors, Glucocorticoid; D011994:Recombinant Proteins; D014157:Transcription Factors; D016572:Cyclosporine; D022021:Tacrolimus Binding Proteins; D016559:Tacrolimus